Tim Levett - Newcells

Retinal platform

An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.


Kidney platform

The most advanced near-physiological high throughput kidney proximal tubule cells (PTC) model to investigate drug transport modalities in vitro.

Lung epithelia model

Lung model

A model to investigate airway physiology, viral infection, drug safety and environmental impacts on lung airway epithelia.

Sinusoid iPSC-derived Liver model

Liver model

We are developing a model of liver sinusoid derived from human induced pluripotent stem cells (iPSC).

Tim Levett

Executive Director

Tim is the chairman for Chairman at NVM Private Equity LLP, responsible for investor relations and represents NVM on the board of several companies including Newcells Biotech. He is also a non-executive director of Northern Venture Trust PLC and Northern 3 VCT PLC. He is twice winner of the prestigious BVCA Deal of the Year award. Prior to NVM, he spent several years in senior management with companies such as Shell UK and International Paints before becoming general manager of Tremco. In Tim’s early career he was an officer in the Royal Navy.

Headshot of Tim Levett